LEUVEN, Belgium, September 11
- ThromboGenics' Significant Achievements Over the Last Year areRecognised in Nominations
ThromboGenics NV (Euronext Brussels: THR), a biotechnology companyfocused on the discovery and development of innovative treatments for eyedisease, vascular disease and cancer, announced today that it has beenshortlisted for both the "Biotech Company of the Year" and "Licensing Deal ofthe Year" awards at the Scrip Awards 2009. These nominations recognise thetransformational year that ThromboGenics has had, and the progress it hasmade toward becoming a profitable, integrated Company focused on cutting edgeophthalmic medicines.
The Biotech Company of the Year award recognises the progress andachievement a biotech company has made within the last twelve months. Duringthe period, ThromboGenics has started the pivotal transatlantic Phase IIIprogramme with microplasmin for back of the eye disease, signed a EUR500million partnership deal with Roche for its novel anti-cancer antibodyTB-403, and moved its novel anti-coagulant TB-402 into Phase II trials.TB-402 is another potential partnership opportunity. There are four othercompanies nominated in this category.
The Licensing Deal of the Year award acknowledges the achievement of aCompany in signing a licensing deal that has both monetary and strategicbenefits to all parties. ThromboGenics signed a major partnership deal withRoche for TB-403 under which the Company and co-development partner BioInventreceived an upfront payment of EUR50 million, an additional EUR450 million inpotential milestones, and double digit royalties on future product sales.There are four other licensing deals nominated in this category.
The Scrip Awards is one of the biotechnology and pharmaceuticalindustry's most prestigious and highly contested awards event. The event isin its fifth year running and the awards ceremony will take place on November18, 2009 in London.
Patrik De Haes, CEO of ThromboGenics, commented, "We are very pleased tohave been shortlisted for both the Biotech Company of the Year and LicensingDeal of the Year awards at this prestigious awards event. The nominations area testament to the significant achievements and progress ThromboGenics hasmade over the last year. The Company is now in the best position to achieveits aim of becoming a profitable, integrated Company focused on cutting edgeophthalmic medicines. We are very proud to be nominated amongst some of themost successful companies in the industry, and look forward to the results inNovember."
ThromboGenics is a biotechnology company focused on the discovery anddevelopment of innovative medicines for the treatment of eye disease,vascular disease and cancer. The Company's lead product microplasmin is inPhase III clinical development for the non-surgical treatment of back of theeye diseases. Microplasmin is also being evaluated in Phase II clinicaldevelopment for additional vitreoretinal indications and as a potentialtherapy for stroke. ThromboGenics is also developing novel antibodytherapeutics in collaboration with BioInvent International; these includeTB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403(anti-PlGF) for cancer.
ThromboGenics has built strong links with the University of Leuven andthe Flanders Institute for Biotechnology (VIB) and has exclusive rights tocertain therapeutics developed at these institutions. ThromboGenics isheadquartered in Leuven, Belgium. The Company is listed on Eurolist byEuronext Brussels under the symbol THR. More information is available athttp://www.thrombogenics.com.
About Scrip World Pharmaceutical News
Scrip World Pharmaceutical News was established in 1972 and - since thattime - has continued to serve as the leading news and information source forthe world's pharmaceutical and biotech industries. Scrip's team of more than20 writers, analysts and editors provide the latest news, features andcommentary from around the globe.
Important information about forward-looking statements
Certain statements in this press release may be considered"forward-looking". Such forward-looking statements are based on currentexpectations, and, accordingly, entail and are influenced by various risksand uncertainties. The Company therefore cannot provide any assurance thatsuch forward-looking statements will materialize and does not assume anobligation to update or revise any forward-looking statement, whether as aresult of new information, future events or any other reason. Additionalinformation concerning risks and uncertainties affecting the business andother factors that could cause actual results to differ materially from anyforward-looking statement is contained in the Company's Annual Report.For further information please contact: ThromboGenics Dr. Patrik De Haes, CEO Tel: +32-16-75-13-10 email@example.com Chris Buyse, CFO Tel: +32-16-75-13-10 firstname.lastname@example.org Citigate Dewe Rogerson Amber Bielecka/ David Dible/ Nina Enegren Tel: +44-207-638-95-71 email@example.com
SOURCE ThromboGenics NV